281 related articles for article (PubMed ID: 6461861)
1. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents.
Mathé G; Schally AV; Comaru-Schally AM; Mauvernay RY; Vovan ML; Machover D; Misset JL; Court B; Bouchard P; Duchier J
Prostate; 1986; 9(4):327-42. PubMed ID: 2947053
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
[TBL] [Abstract][Full Text] [Related]
4. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH.
Gonzalez-Barcena D; Perez-Sanchez P; Ureta-Sanchez S; Berea Dominguez H; Graef-Sanchez A; Becerril Morales M; Comaru-Schally AM; Schally AV
Prostate; 1985; 7(1):21-30. PubMed ID: 2934692
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.
Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1981 Oct; 78(10):6509-12. PubMed ID: 6458815
[TBL] [Abstract][Full Text] [Related]
7. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV
Prostate; 1989; 14(4):291-300. PubMed ID: 2526325
[TBL] [Abstract][Full Text] [Related]
9. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A
Prostate; 1987; 11(3):243-55. PubMed ID: 2960957
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.
Faure N; Labrie F; Lemay A; Bélanger A; Gourdeau Y; Laroche B; Robert G
Fertil Steril; 1982 Mar; 37(3):416-24. PubMed ID: 6800852
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.
Schally AV; Redding TW; Comaru-Schally AM
Med Oncol Tumor Pharmacother; 1984; 1(2):109-18. PubMed ID: 6242477
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH.
Schally AV; Redding TW; Comaru-Schally AM
Prostate; 1983; 4(6):545-52. PubMed ID: 6226942
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
Redding TW; Schally AV
Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
[TBL] [Abstract][Full Text] [Related]
14. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.
Gonzalez-Barcena D; Perez-Sanchez P; Berea-Dominguez H; Graef-Sanchez A; Becerril-Morales M; Comaru-Schally AM; Schally AV
Prostate; 1986; 9(2):207-15. PubMed ID: 2944084
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of prostatic cancer with an LH-RH agonist: the D Trp6 LH-RH. Preliminary results in 30 cases].
Steg A; Chiche R; Boccon-Gibod L; Debré B; Duchier J; Schally AV
Ann Urol (Paris); 1984 Dec; 18(6):388-92. PubMed ID: 6241820
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
[TBL] [Abstract][Full Text] [Related]
17. [Contribution to studies on the treatment of cancer of the prostate with D-Trp6-LH-RH].
Marcellino LR; Campanella A; Bandini M
Biomed Pharmacother; 1987; 41(9-10):468-72. PubMed ID: 2968123
[TBL] [Abstract][Full Text] [Related]
18. Treatment of prostatic cancer with a depot form of a luteinizing hormone-releasing hormone analogue.
Giuliani L; Barreca T; Giberti C; Franceschini R; Martorana G; Brancadoro MT; Salvemini M; Rolandi E
Eur Urol; 1986; 12(6):390-4. PubMed ID: 2949979
[TBL] [Abstract][Full Text] [Related]
19. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
Labrie F; Dupont A; Belanger A; Lachance R; Giguere M
Br Med J (Clin Res Ed); 1985 Aug; 291(6492):369-70. PubMed ID: 3926197
[TBL] [Abstract][Full Text] [Related]
20. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
